keyword
MENU ▼
Read by QxMD icon Read
search

Parkinson's comorbid

keyword
https://www.readbyqxmd.com/read/29150873/survival-in-patients-with-parkinson-s-disease-after-deep-brain-stimulation-or-medical-management
#1
Frances M Weaver, Kevin T Stroupe, Bridget Smith, Beverly Gonzalez, Zhiping Huo, Lishan Cao, Dolores Ippolito, Kenneth A Follett
OBJECTIVE: Deep brain stimulation has been shown to have a significant long-term beneficial effect on motor function. However, whether it affects survival is not clear. In this study, we compared survival rates for Parkinson's disease (PD) patients who underwent deep brain stimulation (DBS) with those who were medically managed. METHODS: A retrospective analysis of Veterans Affairs and Medicare administrative data of veterans with PD who received DBS and were propensity score matched to a cohort of veterans with PD who did not receive DBS between 2007-2013...
November 18, 2017: Movement Disorders: Official Journal of the Movement Disorder Society
https://www.readbyqxmd.com/read/29142796/impact-of-depression-on-hospitalization-and-related-outcomes-for-parkinson-s-disease-patients-a-nationwide-inpatient-sample-based-retrospective-study
#2
Rikinkumar S Patel, Ramkrishna Makani, Zeeshan Mansuri, Upenkumar Patel, Rupak Desai, Amit Chopra
Background Major Depressive Disorder (MDD) is a common comorbidity that significantly affects the quality of life and disease outcomes in Parkinson's disease (PD) patients. No studies have been conducted to our knowledge to address the health care utilization and its outcomes in these patients. The aim of this study is to analyze and discern the differences in the hospitalization outcomes, comorbid conditions, and utilization of procedures in PD patients versus patients with comorbid MDD. Methods We used the Nationwide Inpatient Sample from the Healthcare Cost and Utilization Project from year's 2010-2014...
September 3, 2017: Curēus
https://www.readbyqxmd.com/read/29139041/drug-safety-analysis-in-a-real-life-cohort-of-parkinson-s-disease-patients-with-polypharmacy
#3
Saskia Müller-Rebstein, Claudia Trenkwalder, Jens Ebentheuer, Wolfgang H Oertel, Carsten Culmsee, Günter U Höglinger
BACKGROUND: Polypharmacy is common in geriatric Parkinson's disease (PD) patients in advanced disease stages with multiple comorbidities, bearing multiple risks for drug safety in theory. OBJECTIVE: The aim of this study was to empirically identify the most frequent and relevant contraindications and drug interactions actually occurring and compromising drug safety in PD in real life. METHODS: We conducted a prospective observational study in a multimorbid cohort of PD patients with polypharmacy admitted to a specialized hospital...
November 14, 2017: CNS Drugs
https://www.readbyqxmd.com/read/29109330/vanishing-cerebral-vasculitis-in-a-patient-with-lewy-pathology
#4
Natalia Liapounova, Kamran H Azar, J Max Findlay, Jian-Qiang Lu
Immune-mediated mechanisms are involved in the pathogenesis of both cerebral vasculitis and Parkinson's disease (PD, brainstem-predominant Lewy pathology), but the presentation of cerebral vasculitis with comorbid Lewy pathology has not yet been reported. Here we present a case of pathologically confirmed vasculitis in a 73-year-old male patient whose postmortem examination revealed Lewy pathology diagnostic of PD. This case study suggests a comorbidity of cerebral vasculitis and Lewy pathology, as well as potential pathogenic interactions between these two disorders with immune-mediated mechanisms...
November 7, 2017: Journal of Biomedical Research
https://www.readbyqxmd.com/read/29108985/serotonergic-neurons-mediate-the-anxiolytic-effect-of-l-dopa-neuronal-correlates-in-the-amygdala
#5
Emilie Faggiani, Frederic Naudet, Marcus L F Janssen, Yasin Temel, Abdelhamid Benazzouz
Anxiety in Parkinson's disease is a comorbid non-motor symptom that alters the quality of life of patients. Its neuronal substrates and those of l-Dopa treatment are still poorly known. Using different combinations of monoaminergic system lesions in the rat, we addressed the contribution of these systems in the efficacy of l-DOPA on anxiety and on the neuronal activity of basolateral amygdala (BLA), a brain structure involved in anxiety. Anxiety, locomotor activity and motor performance were assessed using the elevated plus maze, the open field and the skinner box, respectively...
November 3, 2017: Neurobiology of Disease
https://www.readbyqxmd.com/read/29104810/management-of-psychosis-in-parkinson-s-disease-emphasizing-clinical-subtypes-and-pathophysiological-mechanisms-of-the-condition
#6
REVIEW
Raquel N Taddei, Seyda Cankaya, Sandeep Dhaliwal, K Ray Chaudhuri
Investigation into neuropsychiatric symptoms in Parkinson's disease (PD) is sparse and current drug development is mainly focused on the motor aspect of PD. The tight association of psychosis with an impaired quality of life in PD, together with an important underreporting of this comorbid condition, contributes to its actual insufficient assessment and management. Furthermore, the withdrawal from access to readily available treatment interventions is unacceptable and has an impact on PD prognosis. Despite its impact, to date no standardized guidelines to the adequate management of PD psychosis are available and they are therefore highly needed...
2017: Parkinson's Disease
https://www.readbyqxmd.com/read/29102411/what-can-mitochondrial-dna-analysis-tell-us-about-mood-disorders
#7
REVIEW
Takaoki Kasahara, Tadafumi Kato
Variants in mitochondrial DNA (mtDNA) and nuclear genes encoding mitochondrial proteins in bipolar disorder, depression, or other psychiatric disorders have been studied for decades, since mitochondrial dysfunction was first suggested in the brains of patients with these diseases. Candidate gene association studies initially resulted in findings compatible with the mitochondrial dysfunction hypothesis. Many of those studies, however, were conducted with modest sample sizes (N < 1000), which could cause false positive findings...
September 21, 2017: Biological Psychiatry
https://www.readbyqxmd.com/read/29100973/evaluating-psychiatric-symptoms-in-parkinson-s-disease-by-a-clinimetric-analysis-of-the-hopkins-symptom-checklist-scl-90-r
#8
Danilo Carrozzino, Bo Mohr Morberg, Chiara Siri, Gianni Pezzoli, Per Bech
Although psychiatric comorbidity in Parkinson's Disease (PD) has often been studied, the individual psychiatric symptoms have rarely been evaluated from a clinimetric point of view in an attempt to measure how much the symptoms have been bothering or distressing the PD patients. The current study is therefore aimed at evaluating from a clinimetric viewpoint the severity of psychiatric symptoms affecting PD patients by using the Hopkins Symptom Checklist (SCL-90-R) to show its measurement-driven construct validity (scalability)...
November 1, 2017: Progress in Neuro-psychopharmacology & Biological Psychiatry
https://www.readbyqxmd.com/read/29094067/comorbidities-confounding-the-outcomes-of-surgery-for-third-window-syndrome-outlier-analysis
#9
P Ashley Wackym, Heather T Mackay-Promitas, Shaban Demirel, Gerard J Gianoli, Martin S Gizzi, Dale M Carter, David A Siker
Objective: Patients with third window syndrome and superior semicircular canal dehiscence (SSCD) symptoms whose surgical outcomes placed them as outliers were systematically studied to determine comorbidities that were responsible for their poor outcomes due to these confounding factors. Study Design: Observational analytic case-control study in a tertiary referral center. Methods: Twelve adult patients with clinical SSCD syndrome underwent surgical management and had outcomes that did not resolve all of their subjective symptoms...
October 2017: Laryngoscope Investigative Otolaryngology
https://www.readbyqxmd.com/read/29066951/connexin43-and-pannexin-based-channels-in-neuroinflammation-and-cerebral-neuropathies
#10
REVIEW
Denis Sarrouilhe, Catherine Dejean, Marc Mesnil
Connexins (Cx) are largely represented in the central nervous system (CNS) with 11 Cx isoforms forming intercellular channels. Moreover, in the CNS, Cx43 can form hemichannels (HCs) at non-junctional membrane as does the related channel-forming Pannexin1 (Panx1) and Panx2. Opening of Panx1 channels and Cx43 HCs appears to be involved in inflammation and has been documented in various CNS pathologies. Over recent years, evidence has accumulated supporting a link between inflammation and cerebral neuropathies (migraine, Alzheimer's disease (AD), Parkinson's disease (PD), major depressive disorder, autism spectrum disorder (ASD), epilepsy, schizophrenia, bipolar disorder)...
2017: Frontiers in Molecular Neuroscience
https://www.readbyqxmd.com/read/29037787/the-relationship-between-spinal-pain-and-comorbidity-a-cross-sectional-analysis-of-579-community-dwelling-older-australian-women
#11
Katie E de Luca, Lynne Parkinson, Scott Haldeman, Julie E Byles, Fiona Blyth
OBJECTIVES: The aims of this study were to (1) report the prevalence and explore the influence of spinal pain on quality of life and (2) assess the relationship between spinal pain and the type and number of comorbidities. METHODS: This cross-sectional study comprised 579 community-dwelling, older Australian women. Women had "spinal pain" if they marked "yes" to neck pain, upper back pain, mid-back pain, and/or lower back pain. Descriptive statistics and binary logistic regression were performed to report the prevalence and explore the relationship between spinal pain and the type and number of comorbidities...
October 13, 2017: Journal of Manipulative and Physiological Therapeutics
https://www.readbyqxmd.com/read/29037340/-neuropsychiatry-of-movement-disorders
#12
Juan Manuel Orjuela-Rojas, Gustavo Adolfo Barrios Vincos, Melisa Alejandra Martínez Gallego
Movement disorders can be defined as neurological syndromes presenting with excessive or diminished automatic or voluntary movements not related to weakness or spasticity. Both Parkinson's disease (PD) and Huntington's disease (HD) are well-known examples of these syndromes. The high prevalence of comorbid psychiatric symptoms like depression, anxiety, obsessive-compulsive symptoms, hallucinations, delusions, impulsivity, sleep disorders, apathy and cognitive impairment mean that these conditions must be regarded as neuropsychiatric diseases...
October 2017: Revista Colombiana de Psiquiatría
https://www.readbyqxmd.com/read/29032012/continuous-subcutaneous-apomorphine-infusion-in-parkinson-s-disease-patients-with-cognitive-dysfunction-a-retrospective-long-term-follow-up-study
#13
Robbert W K Borgemeester, Teus van Laar
INTRODUCTION: Continuous apomorphine infusion (CAI) is an advanced therapy in fluctuating Parkinson's disease (PD). The use of CAI is controversial in PD patients with cognitive dysfunction including visual hallucinations (VHs), and orthostatic hypotension (OH). This study was set-up to analyze the effectiveness and safety of CAI in elderly PD patients with cognitive dysfunction. METHODS: This new-user cohort study identified fluctuating PD patients who started CAI treatment at the rehabilitation unit of Parkinson Expertise Center (RU-PEC) Groningen, from November 2004 until 2016...
September 29, 2017: Parkinsonism & related Disorders
https://www.readbyqxmd.com/read/29024046/traumatic-brain-injury-in-the-prodromal-period-of-parkinson-s-disease-a-large-epidemiological-study-using-medicare-data
#14
Alejandra Camacho-Soto, Mark N Warden, Susan Searles Nielsen, Amber Salter, David L Brody, Heidi Prather, Brad A Racette
OBJECTIVE: Studies suggest a greater risk of Parkinson's disease (PD) after traumatic brain injury (TBI), but it is possible that the risk of TBI is greater in the prodromal period of PD. We aimed to examine the time-to-TBI in PD patients in their prodromal period compared to population-based controls. METHODS: We identified 89,790 incident PD cases and 118,095 comparable controls aged > 65 years in 2009 using Medicare claims data. Using data from the preceding 5 years, we compared time-to-TBI in PD patients in their prodromal period to controls...
October 10, 2017: Annals of Neurology
https://www.readbyqxmd.com/read/29018160/dopamine-dysregulation-syndrome-in-parkinson-s-disease-a-systematic-review-of-published-cases
#15
Nicola Warren, Cullen O'Gorman, Alexander Lehn, Dan Siskind
OBJECTIVES: Dopamine dysregulation syndrome (DDS) is an uncommon complication of the treatment of Parkinson's disease, characterised by addictive behaviour and excessive use of dopaminergic medication. DDS may frequently go unrecognised or misdiagnosed. We aimed to clarify current understanding of presentation, risk factors, comorbidities and management of DDS. METHODS: Case reports were identified through a systematic search of databases (PubMed, Embase) with the following terms: dopaminergic dysregulation syndrome, hedonistic homeostatic dysregulation, dopamine/levodopa addiction...
October 10, 2017: Journal of Neurology, Neurosurgery, and Psychiatry
https://www.readbyqxmd.com/read/28993094/characterization-of-diplopia-in-non-demented-patients-with-parkinson-s-disease
#16
Katharina A Schindlbeck, Shideh Schönfeld, Wanda Naumann, David J Friedrich, André Maier, Charlotte Rewitzer, Fabian Klostermann, Frank Marzinzik
INTRODUCTION: Although diplopia is considered a frequent symptom of Parkinson's disease (PD), little is known about its clinical manifestation, associated mechanisms and treatment. Here we characterized binocular diplopia in non-demented PD patients in an interdisciplinary setting. METHODS: PD patients were prospectively screened for diplopia, visual hallucinations, problems with spatial perception, contrast sensitivity, presence of blurred vision, and history of ophthalmological comorbidities via interview...
September 29, 2017: Parkinsonism & related Disorders
https://www.readbyqxmd.com/read/28980616/-an-analysis-of-causes-of-death-in-patients-with-parkinson-s-disease
#17
N A Amosova, I G Smolentseva, О А Маslyuk, Yu V Pavlov, E L Gavrilov
AIM: To determine population mortality rate and reasons of death in Parkinson's disease (PD). MATERIAL AND METHODS: To analyze reasons of death, medical death certificates and postmortem records as well as official results of the Federal state statistics service were used. According to the register of Parkinson's disease (PD) patients during 2009-2012, the total mortality was 9.9%. The average age of patients died from the disease was 74.3 ± 2.4 years. The main reasons of death were PD (36...
2017: Zhurnal Nevrologii i Psikhiatrii Imeni S.S. Korsakova
https://www.readbyqxmd.com/read/28976022/development-and-validation-of-prognostic-survival-models-in-newly-diagnosed-parkinson-s-disease
#18
Angus D Macleod, Ingvild Dalen, Ole-Bjørn Tysnes, Jan Petter Larsen, Carl E Counsell
OBJECTIVE: The objective of this study was to develop valid prognostic models to predict mortality, dependency, and "death or dependency" for use in newly diagnosed Parkinson's disease (PD). METHODS: The models were developed in the Parkinsonism Incidence in North-East Scotland study (UK, 198 patients) and validated in the ParkWest study (Norway, 192 patients), cohorts that attempted to identify and follow-up all new PD cases in the study area. Dependency was defined using the Schwab & England scale...
October 4, 2017: Movement Disorders: Official Journal of the Movement Disorder Society
https://www.readbyqxmd.com/read/28967041/tamoxifen-usage-correlates-with-increased-risk-of-parkinson-s-disease-in-older-women-with-breast-cancer-a-case-control-study-in-taiwan
#19
Hsien-Feng Lin, Kuan-Fu Liao, Ching-Mei Chang, Cheng-Li Lin, Shih-Wei Lai
BACKGROUND AND OBJECTIVES: Little is known about the association between tamoxifen usage and risk of Parkinson's disease in women with breast cancer. The present study aimed to evaluate the association between tamoxifen usage and Parkinson's disease in older women with breast cancer in Taiwan. METHODS: We conducted a retrospective nationwide case-control study using the database of the Taiwan National Health Insurance Program. In total, 293 female subjects with breast cancer, aged 65 years and above, who were newly diagnosed with Parkinson's disease between 2000 and 2011 were included...
October 1, 2017: European Journal of Clinical Pharmacology
https://www.readbyqxmd.com/read/28955204/impairment-of-serotonergic-transmission-by-the-antiparkinsonian-drug-l-dopa-mechanisms-and-clinical-implications
#20
REVIEW
Cristina Miguelez, Abdelhamid Benazzouz, Luisa Ugedo, Philippe De Deurwaerdère
The link between the anti-Parkinsonian drug L-3,4-dihydroxyphenylalanine (L-DOPA) and the serotonergic (5-HT) system has been long established and has received increased attention during the last decade. Most studies have focused on the fact that L-DOPA can be transformed into dopamine (DA) and released from 5-HT terminals, which is especially important for the management of L-DOPA-induced dyskinesia. In patients, treatment using L-DOPA also impacts 5-HT neurotransmission; however, few studies have investigated the mechanisms of this effect...
2017: Frontiers in Cellular Neuroscience
keyword
keyword
63617
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"